| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 59 | 2025 | 740 | 6.730 |
Why?
|
| Depressive Disorder | 12 | 2017 | 484 | 2.010 |
Why?
|
| Cognition Disorders | 11 | 2022 | 579 | 1.690 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 736 | 1.360 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 651 | 1.150 |
Why?
|
| Depression | 20 | 2020 | 1365 | 1.070 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2018 | 855 | 0.950 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 17 | 0.950 |
Why?
|
| Anxiety | 13 | 2019 | 1004 | 0.890 |
Why?
|
| Mental Disorders | 7 | 2016 | 890 | 0.850 |
Why?
|
| Aggression | 1 | 2024 | 232 | 0.730 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 317 | 0.670 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 285 | 0.640 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 188 | 0.620 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 85 | 0.610 |
Why?
|
| Dementia | 4 | 2014 | 489 | 0.610 |
Why?
|
| Dystonia | 2 | 2020 | 173 | 0.500 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 150 | 0.490 |
Why?
|
| Veterans | 6 | 2025 | 1788 | 0.490 |
Why?
|
| Cognition | 3 | 2020 | 819 | 0.480 |
Why?
|
| Middle Aged | 43 | 2025 | 29430 | 0.460 |
Why?
|
| Comorbidity | 11 | 2020 | 1628 | 0.440 |
Why?
|
| Aged | 37 | 2025 | 21822 | 0.430 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 4008 | 0.430 |
Why?
|
| Humans | 79 | 2025 | 134225 | 0.430 |
Why?
|
| Panic Disorder | 2 | 2011 | 52 | 0.410 |
Why?
|
| Torticollis | 3 | 2021 | 72 | 0.410 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 473 | 0.410 |
Why?
|
| Delusions | 2 | 2012 | 19 | 0.390 |
Why?
|
| Hallucinations | 2 | 2012 | 27 | 0.390 |
Why?
|
| Health Services | 1 | 2012 | 73 | 0.390 |
Why?
|
| Health Status | 2 | 2012 | 414 | 0.380 |
Why?
|
| Illusions | 1 | 2012 | 8 | 0.380 |
Why?
|
| Drug Utilization | 1 | 2013 | 170 | 0.370 |
Why?
|
| Memory Disorders | 4 | 2020 | 235 | 0.370 |
Why?
|
| Disclosure | 1 | 2013 | 155 | 0.370 |
Why?
|
| Family Health | 3 | 2011 | 268 | 0.360 |
Why?
|
| Nootropic Agents | 2 | 2009 | 27 | 0.360 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 384 | 0.360 |
Why?
|
| Male | 49 | 2025 | 66215 | 0.350 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 34 | 0.340 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2014 | 393 | 0.340 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 7244 | 0.320 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 66 | 0.320 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.310 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 29 | 0.300 |
Why?
|
| Female | 46 | 2025 | 72054 | 0.300 |
Why?
|
| Prevalence | 11 | 2020 | 2685 | 0.290 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 94 | 0.290 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 3119 | 0.260 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2006 | 103 | 0.260 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 58 | 0.250 |
Why?
|
| Psychometrics | 6 | 2013 | 690 | 0.240 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 6 | 0.230 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 10 | 0.230 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2020 | 228 | 0.220 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2003 | 2 | 0.220 |
Why?
|
| Neuropsychological Tests | 8 | 2020 | 992 | 0.210 |
Why?
|
| Adult | 23 | 2021 | 31962 | 0.210 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 18 | 0.210 |
Why?
|
| Indans | 1 | 2004 | 56 | 0.210 |
Why?
|
| Violence | 1 | 2024 | 125 | 0.200 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3759 | 0.200 |
Why?
|
| Psychotropic Drugs | 3 | 2011 | 130 | 0.200 |
Why?
|
| Mental Health Services | 3 | 2015 | 278 | 0.200 |
Why?
|
| HIV Infections | 1 | 2015 | 2073 | 0.190 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 715 | 0.190 |
Why?
|
| Piperidines | 1 | 2004 | 240 | 0.180 |
Why?
|
| Alzheimer Disease | 4 | 2015 | 883 | 0.180 |
Why?
|
| Memory | 3 | 2020 | 358 | 0.180 |
Why?
|
| Pilot Projects | 5 | 2025 | 1493 | 0.170 |
Why?
|
| Hippocampus | 2 | 2020 | 864 | 0.170 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 9 | 0.170 |
Why?
|
| Attention | 2 | 2020 | 202 | 0.170 |
Why?
|
| Neoplasms | 1 | 2015 | 3036 | 0.160 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.160 |
Why?
|
| Internationality | 1 | 2020 | 138 | 0.160 |
Why?
|
| Unconsciousness | 1 | 2019 | 18 | 0.160 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.160 |
Why?
|
| Dreams | 1 | 2019 | 23 | 0.160 |
Why?
|
| Fatigue | 3 | 2010 | 202 | 0.150 |
Why?
|
| Tremor | 1 | 2020 | 135 | 0.150 |
Why?
|
| Encephalitis | 1 | 2020 | 122 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 432 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 260 | 0.150 |
Why?
|
| Sleep | 1 | 2021 | 369 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 103 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 772 | 0.140 |
Why?
|
| Interview, Psychological | 1 | 2018 | 107 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 138 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2019 | 239 | 0.130 |
Why?
|
| Phenotype | 3 | 2021 | 4611 | 0.130 |
Why?
|
| Public Housing | 1 | 2016 | 7 | 0.130 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 494 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 301 | 0.120 |
Why?
|
| Age of Onset | 6 | 2014 | 638 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3678 | 0.120 |
Why?
|
| Psychiatry | 1 | 2019 | 271 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 171 | 0.120 |
Why?
|
| Apathy | 1 | 2015 | 10 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3509 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 254 | 0.110 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 845 | 0.110 |
Why?
|
| Epilepsy | 1 | 2002 | 898 | 0.110 |
Why?
|
| Heterozygote | 3 | 2014 | 732 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2016 | 1044 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 233 | 0.110 |
Why?
|
| ROC Curve | 2 | 2020 | 614 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2011 | 1338 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 166 | 0.100 |
Why?
|
| Role | 1 | 2013 | 30 | 0.100 |
Why?
|
| Mental Health | 2 | 2014 | 374 | 0.100 |
Why?
|
| Research Design | 2 | 2015 | 757 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 430 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1161 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 236 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 332 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 202 | 0.090 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 1982 | 0.090 |
Why?
|
| Mutation | 4 | 2010 | 6350 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 30 | 0.090 |
Why?
|
| Independent Living | 1 | 2012 | 72 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 362 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 38 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 268 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 68 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 327 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 6617 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 32 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 36 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 27 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 507 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1167 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 77 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 76 | 0.080 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 27 | 0.080 |
Why?
|
| alpha-Synuclein | 3 | 2005 | 134 | 0.080 |
Why?
|
| United States | 6 | 2019 | 11798 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 722 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 681 | 0.080 |
Why?
|
| Quality of Life | 5 | 2021 | 2163 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 202 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 808 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1166 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 246 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 94 | 0.070 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2008 | 37 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 34 | 0.070 |
Why?
|
| Lewy Body Disease | 2 | 2004 | 21 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 223 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 594 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 218 | 0.070 |
Why?
|
| Education | 1 | 2007 | 111 | 0.060 |
Why?
|
| MEDLINE | 1 | 2006 | 20 | 0.060 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 5225 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 1079 | 0.060 |
Why?
|
| Motivation | 1 | 2008 | 328 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 1260 | 0.060 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 427 | 0.060 |
Why?
|
| Young Adult | 5 | 2020 | 9963 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2016 | 13105 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 365 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 99 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1183 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 367 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 362 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 169 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 69 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3172 | 0.060 |
Why?
|
| Mammillary Bodies | 1 | 2003 | 2 | 0.050 |
Why?
|
| Diencephalon | 1 | 2003 | 11 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 833 | 0.050 |
Why?
|
| Polysomnography | 1 | 2025 | 153 | 0.050 |
Why?
|
| Consensus | 1 | 2007 | 728 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 151 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 3056 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 1105 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 738 | 0.050 |
Why?
|
| Age Factors | 3 | 2018 | 2997 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 81 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 482 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 146 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2004 | 487 | 0.040 |
Why?
|
| Synucleins | 3 | 2005 | 15 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2005 | 832 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1308 | 0.040 |
Why?
|
| Neurons | 2 | 2008 | 2051 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 169 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 20 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2822 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 454 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2020 | 107 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 315 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1666 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 121 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 128 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 11196 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2020 | 133 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 41 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 428 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 780 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20647 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 334 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 174 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 361 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 2265 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2171 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 127 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 553 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 75 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 195 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 39 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 476 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 141 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 155 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 196 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 457 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 827 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 220 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3869 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 574 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 94 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1512 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1392 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1176 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 35 | 0.020 |
Why?
|
| Brain | 3 | 2010 | 3226 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1388 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 701 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 126 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 136 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 2866 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 300 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 827 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 507 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 641 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 191 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 843 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 440 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1312 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 68 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 712 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 115 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1486 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2004 | 12 | 0.010 |
Why?
|
| Formates | 1 | 2004 | 9 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1909 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2005 | 83 | 0.010 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 3 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 673 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 21 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 41 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 177 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 433 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2319 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 181 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 367 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 251 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1588 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 839 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1630 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 241 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 17591 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 1099 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 598 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1764 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1436 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 163 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 36526 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 5085 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 2538 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3181 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1075 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 19049 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 4012 | 0.010 |
Why?
|